For founders of health tech startups, navigating the U.S. Food and Drug Administration's regulatory landscape is a critical business function, not just a late-stage compliance hurdle. The FDA has established specific frameworks to oversee artificial intelligence and machine learning technologies, and understanding them from day one can shape your product roadmap, clinical strategy, and investor conversations. The key is to determine whether your product is a regulated Software as a Medical Device (SaMD) or a potentially exempt Clinical Decision Support (CDS) tool, and to plan for your algorithm's evolution using a Predetermined Change Control Plan (PCCP).
Navigating the FDA Landscape for AI Medical Devices
The FDA’s approach to AI and machine learning has matured significantly. An action plan released in January 2021 outlined the agency's initial framework for regulating AI/ML-based SaMD. Since then, the FDA has provided more clarity, including finalizing its guidance on Predetermined Change Control Plans in August 2025. This allows AI models to be updated after receiving market clearance without requiring a new submission for every iteration. As of September 2026, the agency has authorized over 1,600 AI-enabled medical devices for marketing in the United States.
This evolving environment means that regulatory strategy must be woven into the fabric of a startup's operations. According to an analysis from Promise Legal Insights, this is not merely a legal exercise. For health tech founders, "understanding this regulatory perimeter is not just a legal compliance exercise — it directly shapes your product roadmap, your clinical validation strategy, and what investors will ask during diligence." Integrating this planning early ensures that product development, clinical validation, and regulatory submissions are aligned, preventing costly delays and rework down the line.
SaMD vs. CDS: The Critical Regulatory Divide
A fundamental determination for any AI health software company is whether its product will be regulated as a medical device. The FDA distinguishes between Software as a Medical Device (SaMD), which is subject to premarket review, and certain types of Clinical Decision Support (CDS) software, which may be exempt.
SaMD is defined as software intended for medical purposes that can function independently of a hardware medical device. An AI algorithm that analyzes medical images to spot abnormalities, for instance, would likely be considered SaMD because it performs a diagnostic function. The FDA classifies these devices based on the risk they pose, considering the seriousness of the medical condition and the importance of the information the software provides to healthcare decisions.
In contrast, the 21st Century Cures Act created an exemption for some CDS software. According to the FDA's final guidance on the topic, issued in September 2022, a tool may be exempt if it allows a healthcare professional to independently review the basis for its recommendations. However, this exemption has prompted concern that clinicians, facing time and resource constraints, may not be able to fully evaluate the software's output, leading to a reliance on unregulated tools that could pose patient risks.
FDA Regulatory Decision Framework for AI Medical Devices
For founders and investors, the distinction between regulated SaMD and potentially exempt CDS software has profound implications for development timelines, costs, and market strategy. The following framework compares these two categories and introduces the role of a Predetermined Change Control Plan (PCCP) for managing regulated AI devices.
| Characteristic | Software as a Medical Device (SaMD) | Clinical Decision Support (CDS) Software |
|---|---|---|
| Regulatory Status | Regulated by the FDA. Requires premarket review through pathways like 510(k), De Novo, or Premarket Approval (PMA). | Potentially exempt from medical device regulation under the 21st Century Cures Act if specific criteria are met. |
| Key Criteria | Performs a medical function (e.g., diagnosis, monitoring) and does not meet all criteria for CDS exemption. Classification is risk-based, depending on the healthcare situation. | Must allow healthcare professionals to independently review the basis for its recommendations and cannot be intended to process images or signals. |
| Implication for AI Updates | Post-market model updates are managed through a Predetermined Change Control Plan (PCCP) that is reviewed and approved by the FDA as part of the initial submission. | If exempt, software updates generally do not require FDA premarket review, though this raises concerns about potential over-reliance on unregulated tools. |
| Primary FDA Guidance | Governed by the FDA's overall framework for SaMD and specific guidance on AI/ML-based software and PCCPs. | Defined by the FDA's final guidance on Clinical Decision Support Software, issued in September 2022. |
Predetermined Change Control Plans (PCCPs): Managing AI Model Evolution
For products classified as SaMD, the dynamic nature of AI presents a unique regulatory challenge. Unlike traditional software, AI/ML models are designed to learn and evolve. To address this, the FDA, in collaboration with international partners like Health Canada and the UK's Medicines and Health Products Regulatory Agency, developed principles for Predetermined Change Control Plans. A PCCP is a crucial component of a premarket submission for an AI-enabled device.
The plan prospectively details the specific modifications a manufacturer intends to make to its device after it is on the market. This includes changes to the model's performance, inputs, and intended use. By having these planned changes reviewed and agreed upon by the FDA before marketing, companies can implement updates without needing to file a new submission for each one. This framework allows manufacturers to mitigate risks like data skewing and concept drift by refining models with real-world data while maintaining safety and effectiveness. The PCCP must also outline how the company will ensure transparency and keep users informed of any modifications.
Strategic Planning for AI Health Tech Founders
Integrating FDA regulatory strategy into a startup's core operations is not an option but a necessity for success. The first step is to make an early, well-reasoned assessment of whether your product is likely to be regulated as SaMD or could qualify for the CDS exemption. This decision dictates the entire product development lifecycle and its associated costs and timelines.
If the product is SaMD, developing a PCCP becomes a central part of the product roadmap. According to Promise Legal Insights, this requires close coordination between engineering, clinical, and regulatory teams long before a launch is considered. The PCCP forces a company to define the intended evolution of its AI model from the outset, turning a potential regulatory bottleneck into a structured, predictable process. This proactive planning can accelerate market entry, improve capital efficiency, and provide a significant competitive advantage in a crowded market.
Strategic Regulatory Planning: Your Path Forward
For health tech founders building the next generation of AI-powered medical tools, the path to market is paved with regulatory milestones. The key decision is not whether to engage with the FDA, but how and when. Founders must proactively integrate FDA regulatory strategy, particularly regarding SaMD/CDS classification and PCCP development, into their product roadmap from the earliest stages. This approach transforms regulation from a barrier into a framework for building safe, effective, and commercially viable products.
A clear indicator of success in this domain is the ability to prepare and submit a premarket application for an AI/ML-based SaMD that includes a comprehensive and well-justified Predetermined Change Control Plan. Achieving this demonstrates a mastery of both the technology and the regulatory landscape, signaling to investors and the market that the company is built for long-term success.
Sources
- Artificial Intelligence-Enabled Medical Devices — U.S. Food and Drug Administration
- Predetermined Change Control Plans — PMC
- FDA AI Medical Device Regulation: A Startup Guide — Promise Legal Insights
- The illusion of safety: A report to the FDA on AI healthcare product approvals - PMC
